Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study

Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study

Background: Even though worldwide death rates from coronavirus disease 2019 (COVID-19) have decreased, the threat of disease progression and death for high-risk groups continues. Few direct comparisons between the available severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals have...

Full description

Bibliographic Details
Main Authors: Sandra Rajme-López, Bernardo A. Martinez-Guerra, Carla M. Román-Montes, Karla M. Tamez-Torres, Andrea C. Tello-Mercado, Karen M. Tepo-Ponce, Zurisadai Segura-Ortíz, Abigail López-Aguirre, Orianlid del Rocío Gutiérrez-Mazariegos, Oswaldo Lazcano-Delgadillo, Rafael Nares-López, María F. González-Lara, David Kershenobich-Stalnikowitz, José Sifuentes-Osornio, Alfredo Ponce-de-León, Guillermo M. Ruíz-Palacios
Format: Article
Language:English
Published: SAGE Publishing 2024-03-01
Series:Therapeutic Advances in Infectious Disease
Online Access:https://doi.org/10.1177/20499361241236582

Internet

https://doi.org/10.1177/20499361241236582

Similar Items